Mologen AG
XHAM:MGNK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Mologen AG
XHAM:MGNK
|
DE |
|
Y
|
YoungLimWon SoftLab Co Ltd
KOSDAQ:060850
|
KR |
|
Prestige Wealth Inc
NASDAQ:AURE
|
HK |
|
Huanlejia Food Group Co Ltd
SZSE:300997
|
CN |
|
Indaptus Therapeutics Inc
NASDAQ:INDP
|
US |
|
Merchants Bancorp
NASDAQ:MBIN
|
US |
|
2020 Bulkers Ltd
OSE:2020
|
BM |
|
D
|
Dundee Sustainable Technologies Inc
CNSX:DST
|
CA |
|
BKW AG
SIX:BKW
|
CH |
|
K
|
Karbon-X Corp
OTC:KARX
|
CA |
|
Chengdu Spaceon Electronics Co Ltd
SZSE:002935
|
CN |
|
Boardwalk Real Estate Investment Trust
TSX:BEI.UN
|
CA |
|
C
|
CSP International Fashion Group SpA
MIL:CSP
|
IT |
|
Z
|
Zhejiang Wanma Co Ltd
SZSE:002276
|
CN |
|
V
|
Volkswagen AG
DUS:VOW
|
DE |
|
Enerplus Corp
TSX:ERF
|
CA |
Mologen AG
MOLOGEN AG engages in the research and clinical development of drugs in the fields of oncology and infectious diseases. The company is headquartered in Berlin, Berlin and currently employs 43 full-time employees. The firm specializes in the research and development of drugs in the fields of oncology and infectious diseases. The firm develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.
MOLOGEN AG engages in the research and clinical development of drugs in the fields of oncology and infectious diseases. The company is headquartered in Berlin, Berlin and currently employs 43 full-time employees. The firm specializes in the research and development of drugs in the fields of oncology and infectious diseases. The firm develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.
